Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TP53 mutations in malignant astrocytomas

W Biernat1, M Debiec-Rychter, R Kordek

  • 1Laboratories of Tumor Biology, Chair of Oncology, University Medical School, Lódź.

Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases.

Neuropathology and applied neurobiology·2019
Same author

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019
Same author

High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2019
Same author

Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH<sub>2</sub>) with anti-inflammatory activity in the mouse models of colitis.

Peptides·2018
Same author

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

TP53 gene mutations are common in malignant astrocytomas, including anaplastic astrocytoma and glioblastoma, in the Polish population. These findings suggest endogenous factors may contribute to tumor development.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Genetics

Background:

  • Astrocytomas are primary central nervous system (CNS) tumors.
  • Malignant astrocytomas, such as anaplastic astrocytoma and glioblastoma, have a poor prognosis.
  • TP53 tumor suppressor gene mutations are frequently observed in these aggressive brain tumors.

Purpose of the Study:

  • To investigate the frequency and spectrum of TP53 gene mutations in Polish patients with anaplastic astrocytoma and glioblastoma.
  • To correlate mutation types with potential etiological factors.

Main Methods:

  • Polymerase chain reaction (PCR) was used to amplify exons 5-8 of the TP53 gene.
  • Single-strand conformation polymorphism (SSCP) analysis was performed to detect mutations.
  • Direct DNA sequencing confirmed the identified TP53 mutations.

Related Experiment Videos

Main Results:

  • TP53 mutations were found in 20% of anaplastic astrocytomas (1 of 5) and 29% of glioblastomas (8 of 28).
  • Exon 8 harbored the most frequent mutations in glioblastomas (6 cases).
  • The observed mutation frequency aligns with international studies.

Conclusions:

  • The study confirms a significant prevalence of TP53 mutations in malignant astrocytomas within the Polish population.
  • The specific types of TP53 mutations suggest the involvement of endogenous etiological factors in the development of these brain tumors.